WO2009004592A1 - Vancomycin compositions - Google Patents

Vancomycin compositions Download PDF

Info

Publication number
WO2009004592A1
WO2009004592A1 PCT/IB2008/052675 IB2008052675W WO2009004592A1 WO 2009004592 A1 WO2009004592 A1 WO 2009004592A1 IB 2008052675 W IB2008052675 W IB 2008052675W WO 2009004592 A1 WO2009004592 A1 WO 2009004592A1
Authority
WO
WIPO (PCT)
Prior art keywords
vancomycin
pharmaceutically acceptable
pharmaceutical composition
polyethylene glycol
process
Prior art date
Application number
PCT/IB2008/052675
Other languages
French (fr)
Inventor
Rahul Dabre
Roshanlal Sandal
Vikrant Thakkar
Girish Kumar Jain
Original Assignee
Wockhardt Research Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN1264MU2007 priority Critical
Priority to IN1264/MUM/2007 priority
Application filed by Wockhardt Research Centre filed Critical Wockhardt Research Centre
Publication of WO2009004592A1 publication Critical patent/WO2009004592A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Abstract

The present invention relates to oral compositions of vancomycin or pharmaceutically acceptable salts thereof. The oral composition is in the form of hard gelatin capsules. The invention also relates to processes for the preparation of such compositions.

Description

Description VANCOMYCIN COMPOSITIONS

[1] Field of the Invention [2] The present invention relates to oral compositions of vancomycin or pharmaceutically acceptable salts thereof. The oral compositions are in the form of hard gelatin capsules. The invention also relates to processes for the preparation of such compositions.

[3] Background of the Invention [4] Vancomycin hydrochloride, a tricyclic vancomycin is derived from Amycolatopsis orientalis (formerly Nocardia orientalis), having the structural Formula I. Vancomycin hydrochloride capsules are indicated for the treatment of staphylococcal entero-colitis and antibiotic-associated pseudo-membranous colitis caused by Clostridium difficile.

Figure imgf000002_0001

[6] FORMULA I [7] British Patent GB 1,596,008 discloses a locking capsule filled with a liquid or other viscous material and having a body part and a cap part telescoped thereon.

[8] British Patent GB 1,590,864 discloses a method of filling hard gelatin capsules with a pharmaceutically active substance which is liquid, semi-solid or a paste like, and includes formulating the active substance into a thixotropic mixture with a pharmaceutically inert carrier and filling the capsule with said thixotropic mixture.

[9] U.S. Patent No. 6,709,675 disclose liquid or pasty thixotropic compositions containing an active substance for filling capsules at room temperature. These compositions are mainly in the form of dispersions supporting amphiphilic excipients. The compositions become fluid by the effect of shearing when they pass through the filling nozzle, and then recover their consistency with sufficient intensity and rapidity to prevent, after filling any leak between the two capsule parts.

[10] U.S. Patent No. 6,171,615 discloses a sustained release theophylline composition in a capsule unit dosage form that includes a gelatin capsule containing a semi-solid matrix, said semi-solid matrix consisting essentially of polyglycolized glycerides, a nucleation enhancer composition consisting essentially of glyceryl mono stearate and polyethylene glycol, and a therapeutically effective amount of theophylline.

[11] U. S. Application No. 20030039956 discloses a pharmaceutical composition for oral delivery of an antimicrobial agent comprising a biopolymer; an antimicrobial agent entrained within or ionically bound to the biopolymer; and a cationic binding agent entrained within or tonically bound to the biopolymer or the antimicrobial agent.

[12] The filling of conventional hard gelatin capsules with liquid or semi-solid pharmaceutical preparations is relatively complex. Further, during sealing problems are encountered because the liquid/semi-solid pharmaceutical preparation penetrates into the space between the external surface of the body part and the internal surface of the cap part of the capsule, which necessitates protection against such leaking by providing a band around the capsule.

[13] For liquid filled hard gelatin capsules, viscosity of the fill material and temperature are two important parameters which must be monitored throughout the capsule filling process. Further, the process is time consuming and requires cost intensive and sophisticated equipment.

[14] Therefore, there exists a need in the art to develop compositions for vancomycin which are easy to handle and are more economical.

[15] Summary of the Invention

[16] In one general aspect there is provided a pharmaceutical composition that includes vancomycin or pharmaceutically acceptable salts thereof and one or more polyethylene glycols.

[17] Embodiments of the compositions may include one or more of the following features. For example, the composition may further include other pharmaceutically acceptable excipients. The other excipients may include one or more of diluents, fillers, binders, lubricants, glidants, and the like.

[18] In another general aspect there is provided a pharmaceutical composition comprising vancomycin or pharmaceutically acceptable salts thereof and one or more polyethylene glycols, wherein rate of dissolution of vancomycin is equal to or greater than that obtained by a vancomycin hydrochloride capsule marketed under the trade name Vancocin hydrochloride®, as measured in water using USP Type I apparatus at 100 rpm.

[19] In another general aspect there are provided processes for preparing pharmaceutical compositions that include vancomycin or pharmaceutically acceptable salts thereof. The process includes: a) mixing vancomycin or pharmaceutically acceptable salts thereof with one or more polyethylene glycols and forming a blend; b) filling the blend into capsules; and (c) heating the capsules at a suitable temperature above 40° C.

[20] In another general aspect there is provided a pharmaceutical composition that includes vancomycin or pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipients characterized by the fact that at least one of the ex- cipients has a melting point below 1000C.

[21] Embodiments of the compositions may include one or more of the following features. For example, the composition may further include other pharmaceutically acceptable excipients. The other excipients may include one or more of diluents, fillers, binders, lubricants, glidants, and the like.

[22] In another general aspect there is provided a solid filled capsule dosage form that includes vancomycin or pharmaceutically acceptable salts thereof and one or more of polyethylene glycols.

[23] Embodiments of the dosage form may include one or more of the following features.

For example, the dosage form may further include other pharmaceutically acceptable excipients. The other excipients may include one or more of diluents, fillers, binders, lubricants, glidants, and the like.

[24] In another general aspect there is provided a stable pharmaceutical composition comprising vancomycin or pharmaceutically acceptable salts thereof and one or more polyethylene glycols, and having less than about 3.5% concentration (w/w) of mono- dechloro vancomycin impurity after three months at 4O0C and 75% relative humidity.

[25] Embodiments of the dosage form may include one or more of the following features.

For example, the dosage form may further include other pharmaceutically acceptable excipients. The other excipients may include one or more of diluents, fillers, binders, lubricants, glidants, and the like.

[26] The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims.

[27] Detailed Description of the Invention

[28] We have now discovered that pharmaceutical compositions of vancomycin or pharmaceutically acceptable salts thereof can be prepared in the form of a solid dispersion with one or more polyethylene glycols. Further, such compositions can be prepared by a process which is easy and fast as the powder can be filled easily in capsules after proper blending and does not require any temperature monitoring. The product of the instant invention provides a similar dissolution pattern as exhibited by the innovator's product marketed under the trade name Vancocin hydrochloride®.

[29] Vancomycin can be present in the form of vancomycin hydrochloride. The poly- ethylene glycols can be selected from one or more of polyethylene glycols with a molecular weight greater than 4000. The ratio of vancomycin to polyethylene glycol in the composition can be varied from about 1:1 to about 1:2. The composition may be in the form of hard gelatin capsules, which are intended predominantly for oral administration.

[30] In general, the pharmaceutical compositions of the invention can be prepared by simple mixing, blending and filling into capsules. T he blending of vancomycin and polyethylene glycol may be carried out in a double cone blender. The filled capsules may be heated using a coating pan at a suitable temperature above 4O0C.

[31] Further embodiment of the present invention includes heating of filled hard gelatin capsule shells at a temperature from about 6O0C to about 650C.

[32] Suitable excipients having a melting point below 1000C may include one or more of polyethylene glycols having a molecular weight greater than 4000.

[33] Suitable binders may include one or more of starch, sugars, gums, low molecular weight hydroxypropylmethyl cellulose, polyvinyl pyrrolidone and hydroxypropyl cellulose, and the like.

[34] Suitable lubricants may include one or more talc, magnesium stearate, polyethylene glycol, hydrogenated vegetable oils, stearic acid, sodium stearyl fumarate, glyceryl behenate, sodium benzoate, and the like.

[35] Suitable glidants may include one or both of colloidal silicon dioxide and talc or magnesium stearate, and the like.

[36] The capsule dosage form developed as a part of invention has been tested for the stability by subjecting the dosage form packaged in HDPE containers and/or Aluminium/ Aluminium pack (hereinafter referred to as AIu/ AIu Pack) at 40°C/75%RH and at 25°C/60%RH for 3 months and is found to be stable after multiple testing.

[37] The present invention is further illustrated by the following examples which are provided merely to be exemplary of the invention and do not limit the scope of the invention. Certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

[38] Examples: The composition of the batches is provided in Table 1, 2. and 3.

Following formulations are representatives of the preferred compositions of the invention. The preparation of examples 1 to 3 is detailed below.

[39] The analytical data/stability data of initial, one-month, two-month and three-month stability for both 125mg and 250mg strength composition (packaged in HDPE and Alu/Alu container) at 40°C/75%RH and at 25°C/60%RH is provided in Table 4 to 7.

[40] Example 1

[41] Table 1 - Composition of Vancomycin capsules. [Table 1] [Table ]

Figure imgf000006_0001

[43] Procedure - Vancomycin Hydrochloride & PEG 6000 were sifted through a mesh and mixed well for few minutes in a double cone blender. This blend was filled in empty hard gelatin capsules. Further, the capsules were rolled in a coating pan at 60-650C for 45-60 min or till the blend in the capsule shell melts.

[44] Example 2 [45] Table 2 - Composition of Vancomycin capsules. [46] [Table 2] [Table ]

Figure imgf000006_0002

[47] Procedure - Vancomycin Hydrochloride & PEG 6000 were sifted through a mesh and mixed well for few minutes in a double cone blender. This blend was filled in empty hard gelatin capsules. Further, the capsules were rolled in a coating pan at 60-650C for 45-60 min or till the blend in the capsule shell melts.

[48] Example 3 [49] Table 3 - Composition of Vancomycin capsules [Table 3] [Table ]

Figure imgf000007_0001

[51] Procedure - Vancomycin hydrochloride, polyethylene glycol 6000 and glyceryl behenate were sifted using a suitable mesh and mixed properly. This blend was filled in empty hard gelatin capsules. Filled capsules were rolled in a coating pan at 60-650C for 45-60 min or till the blend in the capsule shell melts. The capsules were cooled to room temperature.

[52] Stability Data - [53] Table 4 - [54] 125mg Vancomycin Composition packaged in HDPE containers - [55]

[Table 4] [Table ]

Figure imgf000008_0001

[56] Table 5 - [57] 250mg Vancomycin Composition packaged in HDPE containers - [58]

[Table 5] [Table ]

Figure imgf000009_0001

[59] Table 6 - [60] 125mg Vancomycin Composition packaged in HDPE AIu/ AIu Pack [61]

[Table 6] [Table ]

Figure imgf000010_0001

[62] Table 7 - [63] 250mg Vancomycin Composition packaged in AIu/ AIu Pack - [64]

[Table 7] [Table ]

Figure imgf000011_0001

[65] While the invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the invention.

Claims

Claims
[I] A pharmaceutical composition comprising vancomycin or pharmaceutically acceptable salts thereof and one or more polyethylene glycols.
[2] The pharmaceutical composition of claim 1, wherein the polyethylene glycol comprises one or more of polyethylene glycols with a molecular weight more than 4000.
[3] The pharmaceutical composition of claim 2, wherein the polyethylene glycol is polyethylene glycol 6000.
[4] The pharmaceutical composition of claim 1, wherein the vancomycin and polyethylene glycol are mixed in a ratio from about 1:1 to about 1:2.
[5] The pharmaceutical composition of claim 1, further comprising one or more pharmaceutically acceptable excipients.
[6] The pharmaceutical composition of claim 5, wherein the pharmaceutically acceptable excipients comprise one or more of diluents, fillers, binders, lubricants, and glidants.
[7] The pharmaceutical composition of claim 1, wherein the composition is in the form of a hard gelatin capsule.
[8] A pharmaceutical composition comprising vancomycin or pharmaceutically acceptable salts thereof and one or more polyethylene glycols, wherein rate of dissolution of vancomycin is equal to or greater than that obtained by a vancomycin hydrochloride capsule marketed under the trade name Vancocin hydrochloride®, as measured in water using USP Type I apparatus at 100 rpm.
[9] A process for preparing a pharmaceutical composition comprising vancomycin or pharmaceutically acceptable salts thereof, the process comprising:
(a) mixing and blending vancomycin or pharmaceutically acceptable salts thereof and one or more polyethylene glycols;
(b) filling the blend into a capsule; and
(c) heating the capsule at a temperature above 4O0C.
[10] The process of claim 9, wherein the heating of capsule is carried out at a temperature of from about 6O0C to about 650C.
[I I] The process of claim 9, wherein the polyethylene glycol comprises one or more of polyethylene glycols with a molecular weight more than 4000.
[12] The process of claim 11, wherein the polyethylene glycol is polyethylene glycol 6000. [13] The process of claim 9, wherein the vancomycin and polyethylene glycol are mixed in a ratio from about 1 : 1 to about 1 :2.
[14] The process of claim 9, further comprising one or more pharmaceutically acceptable excipients.
[15] The process of claim 14, wherein the pharmaceutically acceptable excipients comprises one or more of diluents, fillers, binders, lubricants, and glidants.
[16] A pharmaceutical composition comprising vancomycin or pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipients, characterized by the fact that at least one excipient has a melting point below 1000C.
[17] The pharmaceutical composition of claim 16, wherein the excipients comprise one or more of polyethylene glycols having a molecular weight greater than 4000.
[18] The pharmaceutical composition of claim 17, wherein the polyethylene glycol is polyethylene glycol 6000.
[19] The pharmaceutical composition of claim 16, wherein the pharmaceutically acceptable excipients comprise one or more of diluents, fillers, binders, lubricants, and glidants.
[20] A solid filled capsule dosage form comprising vancomycin or pharmaceutically acceptable salts thereof and one or more of polyethylene glycols.
[21] The dosage form of claim 20, wherein the polyethylene glycol comprises one or more of polyethylene glycols with a molecular weight more than 4000.
[22] The dosage form of claim 21, wherein the polyethylene glycol is polyethylene glycol 6000.
[23] The dosage form of claim 20, wherein the vancomycin and polyethylene glycol are mixed in a ratio from about 1:1 to about 1:2.
[24] The dosage form of claim 20, further comprising one or more pharmaceutically acceptable excipients.
[25] The dosage form of claim 24, wherein the pharmaceutically acceptable excipients comprises one or more of diluents, fillers, binders, lubricants, and glidants.
[26] A stable pharmaceutical composition comprising vancomycin or pharmaceutically acceptable salts thereof and one or more polyethylene glycols, and having less than about 3.5% concentration (w/w) of monodechloro vancomycin impurity after three months at 4O0C and 75% relative humidity.
PCT/IB2008/052675 2007-07-03 2008-07-03 Vancomycin compositions WO2009004592A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN1264MU2007 2007-07-03
IN1264/MUM/2007 2007-07-03

Publications (1)

Publication Number Publication Date
WO2009004592A1 true WO2009004592A1 (en) 2009-01-08

Family

ID=39885534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/052675 WO2009004592A1 (en) 2007-07-03 2008-07-03 Vancomycin compositions

Country Status (1)

Country Link
WO (1) WO2009004592A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1596008A (en) * 1977-03-29 1981-08-19 Capsugel Ag Sealed capsule
GB2163648A (en) * 1984-08-03 1986-03-05 Nippon Shinyaku Co Ltd Slow release preparations
WO1998055107A1 (en) * 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
WO2001047542A1 (en) * 1999-12-28 2001-07-05 Meiji Seika Kaisha, Ltd. Vancomycin preparations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1596008A (en) * 1977-03-29 1981-08-19 Capsugel Ag Sealed capsule
GB2163648A (en) * 1984-08-03 1986-03-05 Nippon Shinyaku Co Ltd Slow release preparations
WO1998055107A1 (en) * 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
WO2001047542A1 (en) * 1999-12-28 2001-07-05 Meiji Seika Kaisha, Ltd. Vancomycin preparations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOWTLE W J ET AL: "A NEW APPROACH TO VANCOMYCIN FORMULATION USING FILLING TECHNOLOGY FOR SEMISOLID MATRIX CAPSULES" PHARMACEUTICAL TECHNOLOGY, ADVANSTAR COMMUNICATIONS, EUGENE, OR, US, 1 June 1988 (1988-06-01), pages 84,86,88,90-92,97, XP002938041 ISSN: 0147-8087 *
BOWTLE W: "THE APPLICATION OF SEMI-SOLID CAPSULE TECHNOLOGY TO ANTIBIOTIC FORMULATION" BOLLETTINO CHIMICO FARMACEUTICO, SOCIETA EDITORIALE FARMACEUTICA, MILANO, IT, vol. 125, no. 2, 1 January 1986 (1986-01-01), pages 72-74, XP002938042 ISSN: 0006-6648 *

Similar Documents

Publication Publication Date Title
US9592204B2 (en) Oral pharmaceutical dosage forms
KR101290925B1 (en) Coated tablet formulation and method
US20150297734A1 (en) Pharmaceutical composition having reduced abuse potential
US20040259956A1 (en) Titration dosing regimen for controlled release tramadol
US5980942A (en) Zero-order sustained release matrix tablet formulations of carbamazepine
EP0713390B1 (en) Gelatin capsules containing a highly concentrated acetaminophen solution
JP4785847B2 (en) Pramipexole or release tablet formulation is extended including acceptable salt thereof pharmaceutical, their preparation and use thereof
KR100388932B1 (en) Solid pharmaceutical composition comprising a vehicle that sikilsu combining water
KR101019361B1 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US20050191347A1 (en) Pharmaceutical formulations
US8333989B2 (en) Hydrophilic vehicle-based dual controlled release matrix system
US6491950B1 (en) Controlled release pharmaceutical composition
CN102056589B (en) Solid pharmaceutical formulations comprising BIBW 2992
KR20010002590A (en) Composition for Oral Administration of Hardly Soluble Antifungal Agent and Process for the Preparation Thereof
JP2014500305A (en) Tampering resistant (tamperresistant) solid oral dosage forms
WO1997044014A1 (en) Antifungal compositions with improved bioavailability
JP2006514119A (en) Solvent system of a poorly soluble drug dissolution rate is improved
EP1274402B1 (en) Pharmaceutical composition for the controlled release of paracetamol
CN1255852A (en) Novel method and compsns. for drug feeding of taxad alkyl compounds
JP2005531495A (en) Oral capsule formulation with increased physical stability
EP2448406B1 (en) Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
JP2006514052A (en) Solid dispersion comprising a hygroscopic and / or deliquescent drugs
US20150132372A1 (en) Aqueous dispersions of controlled release polymers and shells and capsules thereof
EP2285214A1 (en) Rasagiline soft gelatin capsules
EP1266657A1 (en) Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08763462

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 08763462

Country of ref document: EP

Kind code of ref document: A1